Luca Roncati | Pharmacovigilance | Best Academic Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Luca Roncati | Pharmacovigilance | Best Academic Researcher Award

Link Campus University | Italy

Prof. Dr. Luca Roncati is a distinguished Italian pathologist, physician-scientist, and academic leader whose extensive contributions have significantly advanced modern medical science. With a strong focus on senology, gynecologic oncology, gynecopathology, and hematopathology, he stands as a prominent figure in the global medical community. Dr. Roncati has an impressive record of 228 scientific publications, collectively cited in over 1,073 documents with more than 1,738 total citations, reflecting the profound influence and credibility of his research across various medical disciplines.Renowned for his groundbreaking discoveries, Dr. Roncati is the eponym of the Roncati–Manenti Triad, a key diagnostic concept in gynecologic oncology, and the describer of T rex lymphoma, a rare hematological condition that broadened the understanding of lymphoid malignancies. As a pioneering researcher in COVID-19, his investigations provided critical insights into viral pathogenesis and immune mechanisms, shaping the scientific response during the global pandemic. Furthermore, his innovative work in nanopathology has paved the way for the integration of nanotechnology into modern diagnostic pathology, offering revolutionary approaches to disease detection at the molecular level.Beyond research, Dr. Roncati is a full-time Professor of Pathology at Link Campus University in Rome, where he mentors future medical professionals and drives forward-thinking educational programs in biomedical sciences. Simultaneously, he leads as the Head of the Women’s Health Department at the European Institute of Dermatology in Milan, where his expertise in women’s health, oncology, and diagnostic pathology enhances patient care and clinical outcomes.An award-winning author, academic editor, and inventor of anti-cancer patents, Dr. Roncati’s contributions exemplify the synergy between innovation, clinical excellence, and scientific discovery. His scholarly achievements, coupled with his dedication to advancing medical knowledge, have established him as one of the most influential figures in contemporary pathology and translational medicine. Through his research, publications, and leadership, Prof. Dr. Luca Roncati continues to inspire a new generation of scientists and clinicians in their pursuit of excellence and innovation in healthcare.

Profile: Scopus

Featured Publications

Roncati, L., et al. (2025). Erratum: Long COVID clinical evaluation, research and impact on society: a global expert consensus. Annals of Clinical Microbiology and Antimicrobials.

Roncati, L., et al. (2025). Long COVID clinical evaluation, research and impact on society: a global expert consensus. Annals of Clinical Microbiology and Antimicrobials.

Roncati, L., et al. (2025). pDNA impurities in mRNA vaccines. Editorial, Open Access.

Roncati, L., et al. (2025). Thoracic aortic pseudoaneurysm: Inside its pathophysiology. Vascular.

Roncati, L., et al. (2025). Adjuvant metronomic chemotherapy after surgery in pT1–T2 N0 M0 HER2-positive and ER/PR-positive breast cancer plus targeted therapy, anti-hormonal therapy, and radiotherapy, with or without immunotherapy: A new operational proposal. Editorial, Open Access.

Roncati, L., et al. (2025). Ozone–oxygen therapy to prevent HPV-related cancers of the lower gynecological tract in infected patients: The rationale for further developments. Cancers. [Open Access]

Roncati, L., et al. (2025). COVID-19 and upper limb compression neuropathies: A review. Review Article, Open Access.

Muhammad Musa Khan | Drug Safety and Risk Management | Best Researcher Award

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Muhammad Musa Khan | Drug Safety and Risk Management | Best Researcher Award

Hainan Intitute of Zhejiang University | China

Assoc. Prof. Dr. Muhammad Musa Khan is an accomplished entomologist and agricultural researcher whose scientific endeavors bridge environmental toxicology, pest management, and agroecological sustainability. His academic journey reflects a strong foundation in agricultural entomology, leading to advanced expertise in pest control and ecotoxicology. Currently serving as an Associate Researcher at the Hainan Institute of Zhejiang University in China, Dr. Khan plays a leading role in investigating pesticide toxicity, insecticide resistance, and the ecological risks associated with chemical pest management in rice agroecosystems. His leadership and research contributions under the guidance of distinguished scientists have advanced global understanding of integrated pest management strategies and sustainable agricultural practices.Dr. Khan’s research experience extends to his postdoctoral work at South China Agricultural University, where he explored the management of whiteflies and diamondback moths through ultraviolet light exposure, revealing insights into immunity suppression and its implications for biological control agents. His earlier doctoral research at Huazhong Agricultural University focused on assessing the ecological risks of modern insecticides such as emamectin benzoate and chlorantraniliprole on beneficial predators like Paederus fuscipes, a natural enemy of the brown planthopper. He also evaluated the “push and pull” pest management approach using essential oils and synthetic chemicals, blending ecological knowledge with innovative pest control methods. His master’s and undergraduate studies laid the foundation for his deep understanding of insect–plant interactions, particularly in cotton crops where he analyzed morphological and biochemical traits contributing to pest resistance.A versatile and skilled experimental researcher, Dr. Khan possesses extensive expertise in molecular and biochemical methodologies. His technical proficiency includes DNA and RNA extraction, PCR, RT-qPCR, gene cloning, enzyme activity analysis, and protein profiling through SDS-PAGE and Western blotting. Additionally, his software expertise spans advanced data analysis and visualization platforms such as R-Studio, SPSS, SigmaPlot, and MEGA-X, along with strong skills in scientific illustration using BioRender and AI-based tools for bioinformatics. This blend of laboratory precision and digital innovation positions him as a modern scientist capable of integrating complex datasets into actionable scientific insights.

Profile: Google Scholar

Featured Publications

Siddiqui, J. A., Khan, M. M., Bamisile, B. S., Hafeez, M., Qasim, M., & Rasheed, M. T., et al. (2022). Role of insect gut microbiota in pesticide degradation: A review. Frontiers in Microbiology.

Hafeez, M., Ullah, F., Khan, M. M., Li, X., Zhang, Z., Shah, S., Imran, M., Assiri, M. A., et al. (2022). Metabolic-based insecticide resistance mechanism and ecofriendly approaches for controlling of beet armyworm Spodoptera exigua: A review. Environmental Science and Pollution Research.

Siddiqui, J. A., Bamisile, B. S., Khan, M. M., Islam, W., Hafeez, M., Bodlah, I., & Xu, Y. (2021). Impact of invasive ant species on native fauna across similar habitats under global environmental changes. Environmental Science and Pollution Research.

Khan, M. M., Nawaz, M., Hua, H., Cai, W., & Zhao, J. (2018). Lethal and sublethal effects of emamectin benzoate on the rove beetle Paederus fuscipes, a non-target predator of rice brown planthopper Nilaparvata lugens. Ecotoxicology and Environmental Safety.

Liu, S., Zhao, J., Hamada, C., Cai, W., Khan, M., Zou, Y., & Hua, H. (2019). Identification of attractants from plant essential oils for Cyrtorhinus lividipennis, an important predator of rice planthoppers. Journal of Pest Science.

Sandrine Colas | Drug Safety and Risk Management | Pharmaceutical Research Impact Award

Published on by Top Pharmaceutical

Dr. Sandrine Colas | Drug Safety and Risk Management | Pharmaceutical Research Impact Award

Pharmacoepidemiologist at Sanofi | France

Dr. Sandrine Colas is a Senior Pharmacoepidemiologist with over a decade of expertise in pharmacoepidemiology, biostatistics, and real-world data research. She has led global pharmacovigilance initiatives, innovative AI-driven projects, and regulatory strategies at renowned institutions like Sanofi, IQVIA, and EPIPHARE-ANSM. With extensive experience in risk-benefit assessment, AI and NLP applications in healthcare, and cross-functional collaboration, she has significantly impacted regulatory decision-making and scientific dissemination. Dr. Colas is widely recognized for her operational excellence, leadership, and contributions to real-world evidence studies, presenting at major scientific forums and mentoring future experts in pharmacoepidemiology and public health research.

Publication Profile 

Orcid

Education 

Dr. Sandrine Colas holds a Ph.D. in Public Health, Epidemiology from Université Paris-Saclay, where she specialized in pharmacoepidemiology and advanced biostatistics. She also earned an MSc in Public Health, Epidemiology from Université Paris-Sud and another MSc in Food Industries Technologies from ENSAIA, strengthening her interdisciplinary foundation. Additionally, she completed a degree in Biomedical Engineering at UTC/ENSP, gaining technical and analytical expertise essential for healthcare data analysis and medical research. This diverse educational background has enabled her to integrate statistical modeling, real-world data analytics, and public health perspectives to address complex issues in drug safety and healthcare innovation.

Experience 

Dr. Sandrine Colas currently serves as Senior Pharmacoepidemiologist at Sanofi R&D, leading the Valproate PASS Program, TANGO study, and AI-based healthcare innovations while collaborating with PRAC/EMA regulatory bodies. She previously directed epidemiological research at IQVIA, managing real-world evidence studies and regulatory responses. At EPIPHARE-ANSM, she contributed to post-authorization safety studies (PASS), risk management plans (RMPs), and mentored postgraduate students. Across roles, she has excelled in cross-functional collaboration, strategic leadership, scientific presentations, and regulatory submissions. Her work integrates real-world evidence, AI analytics, and clinical data insights, shaping global pharmacovigilance practices and improving drug safety monitoring in real-world healthcare settings.

Awards and Honors 

Dr. Sandrine Colas has received multiple recognitions for her leadership and scientific contributions. At Sanofi, she earned the 2022 Development Award for Operational Excellence and Outstanding Impact Awards in 2022 and 2024 for her role in AI-driven pharmacovigilance innovations. Her pioneering work on AI-NLP-LLM applications in healthcare research was ranked among the Top 5% Abstracts at ISPOR 2024, where she also won the Best Podium Award. She has presented widely at international conferences including ISPE, EBMT, and ISPOR, reflecting her commitment to advancing pharmacoepidemiology, regulatory science, and real-world data analytics through high-impact publications and innovative research methodologies.

Research Focus 

Dr. Sandrine Colas specializes in pharmacoepidemiology, regulatory science, and real-world data analytics. Her research focuses on drug safety, post-authorization studies, and risk-benefit assessments using large healthcare datasets like SNDS. She has integrated AI, natural language processing (NLP), and advanced analytics to enhance drug surveillance, predict adverse outcomes, and support regulatory decision-making. Her interests also include AI-driven pharmacovigilance innovations, real-world evidence generation, and methodological advancements in epidemiological research. Through cross-disciplinary collaboration, she aims to strengthen evidence-based regulatory policies, optimize patient safety strategies, and bridge the gap between clinical research, real-world practice, and global health policy in pharmaceutical development.

Publication Top Notes

Effectiveness of the Additional Risk Minimisation Measures for Valproate Among Healthcare Professionals and Patients: A Cross‐Sectional Survey in Six European Countries

Considerations for practical use of tree-based scan statistics for signal detection using electronic healthcare data: a case study with insulin glargine

Reply to the Letter to the Editor: Is There a Cardiotoxicity Associated With Metallic Head Hip Prostheses? A Cohort Study in the French National Health Insurance Databases

Is There a Cardiotoxicity Associated With Metallic Head Hip Prostheses? A Cohort Study in the French National Health Insurance Databases

Relative impact of hospital and surgeon procedure volumes on primary total hip arthroplasty revision: a nationwide cohort study in France

Exchangeable Femoral Neck (Dual-Modular) THA Prostheses Have Poorer Survivorship Than Other Designs: A Nationwide Cohort of 324,108 Patients

Association between Exposure to Benzodiazepines and Related Drugs and Survivorship of Total Hip Replacement in Arthritis: A Population-Based Cohort Study of 246,940 Patients

Association Between Total Hip Replacement Characteristics and 3-Year Prosthetic Survivorship

Inondation des capteurs de pression sanguine des générateurs–moniteurs d’hémodialyse

Conclusion

Given her leadership in pharmacovigilance research, AI-based healthcare innovations, and extensive real-world data studies, Dr. Sandrine Colas is a strong candidate for the Pharmaceutical Research Impact Award. Her impactful publications, regulatory contributions, and commitment to improving drug safety and healthcare decision-making reflect the award’s core values. With minor expansions into emerging interdisciplinary fields, she could further solidify her status as a global leader in pharmaceutical research innovation and evidence-based healthcare advancements.